Dr. Denise Scots-Knight Chief Executive Officer

Dr. Denise Scots-Knight

Chief Executive Officer

Denise is CEO, a board member and co-founder of Mereo. Denise has over 25 years’ experience in the biopharmaceutical industry in R&D management and venture capital. 

She was in R&D management at Amersham and Fisons and a senior executive at Scientific Generics before joining Rothschild Asset Management as an investment manager. In 1999 she joined Nomura and was a Managing Director leading the life science investments in biotechnology companies. She led the Phase4 Partners MBO from Nomura in 2010.

Denise had served on many US and European private and public boards. She is currently a board member of Elanco Animal Health Inc. Denise has a PhD and BSc (Hons) from Birmingham University and was a Fulbright scholar at UC Berkeley.

Dr. Peter Fellner Chairman

Dr. Peter Fellner


Peter has previously served on the Boards of a wide range of life science companies, including as Chairman of the MedTech company Consort Medical plc until April 2019, Chairman of Vernalis plc until October 2018, Chairman of Ablynx NV from November 2013 until January 2018, Vice-Chairman of Astex Pharmaceuticals Inc. until its sale to Otsuka in 2013, Chairman of Optos plc from 2000 until its acquisition by Nikon Corporation in 2015, Director of the global biopharmaceutical company UCB SA from 2005 to 2014 and Chairman of Acambis plc from 2006 until its acquisition by Sanofi in 2008.

He was Chairman of Celltech Group plc until its acquisition by UCB in 2004, having been CEO from 1990. Before joining Celltech he was CEO of Roche UK from 1986 to 1990. He served as a member of the Medical Research Council from 2000 to 2007.

Dr. Anders Ekblom Non-Executive Director

Dr. Anders Ekblom

Non-Executive Director

Anders has extensive experience as an executive and leader with broad business knowledge from senior roles in the biopharmaceutical industry, with global experience delivering products, projects, productivity and change management.

He is currently Chairman/Non-Executive Board member of several biotech companies. During two decades at AstraZeneca, he was a member of global executive teams including Executive VP Global Medicines Development, Global Head Clinical Development, Global Therapy Area Head, Global Head Science & Technology Integration, and CEO AstraZeneca AB Sweden.

Anders is also a board certified MD (Anaesthesiology and Intensive Care), PhD, DDS, and Associate Professor at Karolinska Institute, Stockholm, Sweden and a fellow of the Royal Swedish Academy of Engineering Sciences.

Mike Wyzga crop.png
Michael Wyzga Deputy Chair

Michael Wyzga

Deputy Chair

Michael Wyzga served as a director of OncoMed from October 2013 until the closing of the Merger. Mr. Wyzga is currently the President of MSW Consulting Inc., a strategic consulting group focused in the life sciences area.

From December 2011 until November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as Chief Financial Officer from July 1999 until November 2011.

Mr. Wyzga is a member of the boards of directors of Exact Sciences Corporation and LogicBio and is Chairman of the board of directors of GenSight Biologics S.A. and of X4 Biologics. Mr. Wyzga previously served as a member of the boards of directors of Idenix Pharmaceuticals, Inc. and Altus Pharmaceuticals, Inc., and as a member of the supervisory board of Prosensa Holding B.V. He received an M.B.A. from Providence College and a B.S. from Suffolk University.

Dr Deepa Pakianathan Non-Executive Director

Dr Deepa Pakianathan

Non-Executive Director

Deepa is a Managing Member at Delphi Ventures and leads all of the firm’s biotechnology investment activities. She joins the Mereo Board subsequent to the merger with OncoMed Pharmaceuticals. She currently serves on the boards of Theravance Biopharma Inc (Nasdaq:TBPH), Calithera Biosciences (Nasdaq: CALA), and Karyopharm Therapeutics (Nasdaq:KPTI). 

Deepa joined Delphi in 2001 to build and lead the firm’s biotechnology investment practice. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at J.P. Morgan. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group.

She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Deepa received her Ph.D. and MS from Wake Forest University and her MSc and BSc from the University of Bombay.

Dr. Jeremy Bender Non-Executive Director

Dr. Jeremy Bender

Non-Executive Director

Jeremy is a senior biopharma leader with broad experience driving strategic decisions and transactions. He was recently appointed Chief Executive Officer of DayOne Biopharmaceuticals, Inc., focused on oncology. Previously Jeremy served as Vice President of Corporate Development at Gilead Sciences, Inc., where he was responsible for development and negotiation of partnerships, alliances, joint ventures, equity investments, licensing agreements and M&A transactions including Gilead’s $4.9bn acquisition of Forty Seven, Inc., and the establishment of a 10-year partnership with Arcus Biosciences Inc., to advance next-generation cancer immunotherapies.

Jeremy joined Gilead from Tizona Therapeutics, Inc., where he was Chief Operating Officer. Prior to Tizona, he was Chief Business Officer of Sutro Biopharma, Inc.. During his time at Sutro, he successfully completed partnering transactions with Celgene Corporation and EMD Serono.

Jeremy received his undergraduate degree in Biological Sciences from Stanford University and his Microbiology & Immunology from the University of Colorado, where he worked on peripheral T-cell selection in the labs of Philippa Marrack and John Kappler. He also holds an M.B.A. from the MIT Sloan School of Management.


Brian Schwartz (1).jpg
Dr. Brian Schwartz Non-Executive Director

Dr. Brian Schwartz

Non-Executive Director

Brian has wide-ranging experience as a drug development expert in pharmaceutical and biotechnology industries, spanning several therapeutic areas including oncology, hematology, dermatology, neurology and rare diseases.

During the past decade Brian has served as Senior Vice President, Head of Research & Development and Chief Medical Officer of ArQule Inc., which was  acquired for $2.7bn by Merck & Co. in 2020. Prior to ArQule Inc., Brian was CMO at  Ziopharm, having previously held several senior leadership roles at Bayer and LEO Pharma.

Brian is a Board Member of Cyclacel Pharmaceuticals and Enlivex Therapeutics, an advisor for the California Institute of Regenerative Medicine and acts as an independent consultant for numerous biotech companies.

Brian received his medical degree from the University of Pretoria, South Africa, completed a fellowship at the University of Toronto, Canada and practised medicine prior to his career in the biopharmaceutical industry.

Dr. Pierre Jacquet Non-Executive Director

Dr. Pierre Jacquet

Non-Executive Director

Dr. Jacquet is currently Managing Director and Vice Chairman of L.E.K. Consulting’s Healthcare practice. He has served in a variety of leadership roles over 20 years at L.E.K., including Global Head, Healthcare Practice, Global Leadership Team, the Americas management committee, and various partner operating committees. Prior to joining L.E.K. in 2001, Dr. Jacquet was trained as a surgical resident at University of Liège, Belgium and served as a Fellow at the Washington Cancer Institute, where he authored over 40 publications and presentations. In addition to serving on Mereo’s Board of Directors, Dr. Jacquet is a Director of Exact Sciences, on the Advisory Board of Life Science Cares, and previously served as a Director of Osprey Pharmaceuticals. He earned a Master of Business Administration from the Darden Graduate School at the University of Virginia, graduated Magna Cum Laude in Medicine from the University of Liège in Belgium and was awarded a Summa Cum Laude Doctor of Philosophy in biomedical sciences from the University of Liège in Belgium.

Board Committees

Learn more about the Board committees: 1) Audit and Risk, 2) Remuneration, 3) Nomination and 4) Research & Development.

View Our Board Committees